Dendreon Corp (DNDNQ) 0.0325 $DNDNQ Global Cancer

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dendreon Corp (DNDNQ) 0.0325 $DNDNQ

Global Cancer Immunotherapy Market Outlook 2020
M2 - Fri Jun 12, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3t28xc/global_cancer) has announced the addition of the "Global Cancer Immunotherapy Market Outlook 2020" report to their offering. Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects. Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years. Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts. Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data. New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future. Cancer Immunotherapies Included in Report: Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines "Global Cancer Immunotherapy Market Outlook 2020" Report Highlight: - Introduction & Classification of Cancer Immunotherapy - Global Cancer Immunotherapy Pipeline by Company, Indication & Phase - Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication - Global Cancer Immunotherapy Pipeline: 1834 Drugs - Marketed Cancer Immunotherapies: 113 Drugs - Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb - Cancer Vaccines Pipeline: 312 Vaccines - Marketed Cancer mAb: 36 mAb - Marketed Cancer Vaccines: 12 Vaccines Key Topics Covered: 1. Introduction to Cancer Immunotherapy 2. Classification of Cancer Immunotherapy 3. Cancer Immunotherapy by Vaccines 4. Cancer Immunotherapy by Monoclonal Antibodies 5. Cancer Immunotherapy by Adoptive Cell Transfer 6. Cancer Immunotherapy by Immune Checkpoint Inhibitors 7. Cancer Immunotherapy by Immunomodulators 8. Cancer Immunotherapy by Cytokines 9. Cancer Immunotherapy by Interleukins 10. Cancer Immunotherapy by Interferon 11. Cancer Immunotherapy by GM-CSF 12. Cancer Immunotherapy Market Overview 13. Global Cancer Immunotherapy Market Dynamics 14. Global Cancer Immunotherapy Market Future Prospects 15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase 16. Marketed Cancer Cell Therapies Drugs Clinical Insight 17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase 18. Marketed Cancer Cytokines Drugs Clinical Insight 19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase 20. Marketed Cancer Immunomodulators Clinical Insight 21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase 22. Marketed Cancer Vaccines Clinical Insight 23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase 24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight 25. Competitive Landscape - Abbvie - Advaxis - Altor BioScience - Amgen - Biogen Idec - Biogenomics - Celldex Therapeutics - Dendreon Corporation - Eli Lilly - Expression Genetics - Galena Biopharma - Genmab - Gilead Sciences - GlaxoSmithKline - IRX Therapeutics - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Pfizer - Philogen - Regulon - Roche - Seattle Genetics - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/3t...bal_cancer
INO: 7.46 (+0.19), BIIB: 388.23 (-11.06), NWBO: 10.82 (+0.49), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), CLDX: 24.89 (+0.42), NLNK: 46.82 (+2.23), AMGN: 154.10 (+2.79), GALE: 1.63 (+0.10), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65), IMUC: 0.49 (+0.01), NVS: 103.22 (+3.20)

US Cancer Vaccine Market Outlook 2020
M2 - Tue May 26, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhhwzb/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2020" report to their offering. Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies. Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years. Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines in encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy. Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pyroli and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies. US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines. "US Cancer Vaccine Market Outlook 2020" Report Highlight: - US Cancer Vaccine Market Analysis - Cancer Vaccine with Orphan Status - US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase - US Cancer Vaccine Clinical Pipeline: 187 Vaccines - Clinical Insight of Marketed Cancer Vaccines in US - Marketed Cancer Vaccine in US: 5 Vaccines - FDA Regulations for Clinical Trials of Cancer Vaccines Clinical Insight of Marketed Cancer Vaccines in US - Bladder Cancer Vaccine - ID Biomedical (PACIS?) - Bladder Cancer Vaccine - Organon Teknika (OncoTICE) - Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil?) - Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix?) - Prostate Cancer - Dendreon Corporation (Provenge?) Companies Mentioned - Aduro BioTech - Advaxis - Antigen Express - Argos Therapeutics - Bavarian Nordic - Celldex Therapeutics - Cosmo Pharmaceuticals - Dendreon Corporation - GSK - Galena Biopharma - Generex Biotechnology - Gradalis - Merck - NewLink Genetics - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/bh...er_vaccine
ARGS: 6.45 (+0.69), ADRO: 30.58 (+0.28), MRK: 57.95 (+0.57), CLDX: 24.89 (+0.42), NLNK: 46.82 (+2.23), GALE: 1.63 (+0.10), GSK: 42.45 (+0.65)

Dendritic Cell and CAR-T Therapies Market, 2014 - 2024
PR Newswire - Wed May 13, 1:01PM CDT
INTRODUCTIONCancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).

After Failure Of Phase 3 Trial, Aerie Pharmaceuticals Struggles To Find Value
Edward Vranic, CFA - at Seeking Alpha - Tue Apr 28, 7:46AM CDT

EYES: 14.10 (+0.67), AERI: 17.80 (+0.12)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.40 (+0.03), NBS: 2.25 (-0.09), OSIR: 19.31 (+0.65), BCLI: 3.46 (-0.03), MDVN: 106.81 (-2.19), INO: 7.46 (+0.19), CYTX: 0.47 (+0.01), STEM: 0.52 (+0.01), JUNO: 52.05 (+1.72), ATHX: 1.14 (-0.01), CUR: 1.69 (-0.01), BLUE: 159.03 (+0.60), VRTX: 122.95 (+2.06), AMGN: 154.10 (+2.79), KERX: 9.81 (+0.11), OMER: 17.33 (+0.29), KITE: 64.36 (+1.05), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), TEVA: 61.38 (-0.75)

Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 99.53 (+1.13), INO: 7.46 (+0.19), NWBO: 10.82 (+0.49), MRK: 57.95 (+0.57), CLDX: 24.89 (+0.42), NLNK: 46.82 (+2.23), GALE: 1.63 (+0.10), IMUC: 0.49 (+0.01), NVS: 103.22 (+3.20)

Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 34.36 (+0.50), AMRN: 2.41 (+0.02)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 43.48 (-0.10), CASM: 1.24 (-0.04), AMRN: 2.41 (+0.02), XON: 46.54 (+1.02), OSIR: 19.31 (+0.65), CPIX: 7.20 (+0.09), AMED: 41.52 (+0.58), CTIC: 1.91 (+0.03), INSY: 37.53 (+0.49), ECYT: 5.43 (+0.17), CMRX: 46.90 (+1.08), KYTH: 74.70 (-0.05), TRIB: 18.05 (+0.17), GALE: 1.63 (+0.10), ARNA: 4.29 (+0.04), XLRN: 30.03 (+0.20), ACRX: 4.20 (+0.02), ENDP: 83.12 (+2.66), DPLO: 48.64 (+1.85), SLXP: 172.96 (+0.15), PPHM: 1.29 (+0.06), MYL: 71.22 (+0.87), CBPO: 111.03 (+7.77), RGEN: 40.28 (+1.65), HALO: 22.78 (+0.38), ALIM: 4.56 (+0.15), ACHN: 8.68 (+0.14), GERN: 4.22 (+0.13), DARA: 0.88 (+0.01), SCMP: 18.15 (+0.87), ICPT: 247.71 (+4.45), CDXS: 3.64 (+0.06), PCRX: 67.54 (+0.20), PBYI: 106.25 (-2.12), FOLD: 14.48 (+0.44)

Valeant Pharmaceuticals Buys Salix Pharmaceuticals in $14.5 Billion Megadeal
at The Street - Mon Feb 23, 11:03AM CST
Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal.
AGN: 312.13 (+8.03), VRX: 232.32 (+8.93), ACT: 298.98 (-2.94), SHPG: 250.34 (+7.35), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), SLXP: 172.96 (+0.15), ABBV: 69.23 (+1.26), HSP: 89.15 (+0.02)

Report: Valeant to buy Salix for $10.1B
Seeking Alpha - at Seeking Alpha - Sun Feb 22, 5:53AM CST

ENDP: 83.12 (+2.66), VRX: 232.32 (+8.93), SHPG: 250.34 (+7.35), SLXP: 172.96 (+0.15)

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 232.32 (+8.93), ACT: 298.98 (-2.94), MDT: 74.37 (+1.28), XON: 46.54 (+1.02), CTIC: 1.91 (+0.03), PFNX: 19.47 (+0.49), JNJ: 99.53 (+1.13), ANTM: 159.73 (+1.15), NVAX: 11.98 (-0.13), SHPG: 250.34 (+7.35), ABBV: 69.23 (+1.26), TBPH: 12.29 (+0.36), SNY: 51.49 (+2.71), ALQA: 5.19 (+0.09), REGN: 526.01 (+16.98), ONCY: 0.58 (+0.03), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), EPRS: 6.00 (+0.35), AMGN: 154.10 (+2.79), NKTR: 11.40 (+0.22), ZTS: 46.96 (+0.39), GILD: 113.74 (+0.38), ACHN: 8.68 (+0.14), GERN: 4.22 (+0.13)

Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST

TSLA: 259.15 (+1.23), VRX: 232.32 (+8.93), AMX: 20.66 (+0.20), HAL: 41.33 (+0.02), PBR: 8.38 (+0.10), ANTM: 159.73 (+1.15), FSLR: 44.03 (+0.38), SPY: 207.48 (+2.58), QQQ: 107.65 (+1.62), ARMH: 47.42 (+0.06), MSFT: 44.61 (+0.09), AAPL: 123.28 (+3.21), INTU: 104.36 (+0.78)

Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST

VRX: 232.32 (+8.93)

Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 232.32 (+8.93), VRX.TO: 294.65 (+11.22)

Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
PR Newswire - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE® (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon" . In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014.
VRX: 232.32 (+8.93), VRX.TO: 294.65 (+11.22)

Is Valeant Making A Mistake By Purchasing Rights To Provenge?
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:22PM CST

VRX: 232.32 (+8.93)

Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST

BCRX: 15.49 (+0.09), ACT: 298.98 (-2.94), VRX: 232.32 (+8.93), PCYC: 261.25 (+1.70), ZSPH: 58.93 (+1.96), RMTI: 16.97 (+0.71), BCLI: 3.46 (-0.03), SIEN: 25.38 (+1.02), JNJ: 99.53 (+1.13), ECYT: 5.43 (+0.17), SNY: 51.49 (+2.71), LENS: 7.05 (+0.23), REGN: 526.01 (+16.98), SYK: 96.37 (+0.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), AMGN: 154.10 (+2.79), APPY: 0.45 (-0.01), MNKD: 5.38 (+0.25), CELG: 118.84 (+1.97), ISRG: 487.87 (+6.40), GILD: 113.74 (+0.38), ANIP: 62.22 (+1.36), MRK: 57.95 (+0.57), ALXN: 192.53 (+4.37), CCXI: 8.60 (+0.19), ICPT: 247.71 (+4.45), AEZS: 0.24 (+0.01), ATRS: 2.26 (+0.09), NASH: 33.53 (+0.33)

Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
Dana Blankenhorn - at Seeking Alpha - Fri Jan 30, 11:12AM CST

BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), XOM: 82.22 (+0.62), AMGN: 154.10 (+2.79), REGN: 526.01 (+16.98), SLB: 83.96 (+0.41), CELG: 118.84 (+1.97)

Wall Street Breakfast: Amazon Shares Surge After Profit Beat
Wall Street Breakfast - at Seeking Alpha - Fri Jan 30, 5:31AM CST

AMZN: 443.51 (+9.12), VRX: 232.32 (+8.93), SHAK: 50.50 (+0.07), OSTK: 22.48 (+0.32), CCRN: 13.19 (+0.23), LPG: 16.22 (+0.48), GOOG: 530.13 (+9.45), CVC: 26.67 (+1.82), PBR: 8.38 (+0.10), V: 68.42 (+1.37), SPY: 207.48 (+2.58), QQQ: 107.65 (+1.62), TRP: 39.38 (+0.64), XCO: 0.81 (-0.09), GOOGL: 556.11 (+11.46), HMC: 31.68 (+0.38), VZ: 47.00 (+0.74)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 33

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 136

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 0

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 108

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Companies Faces Turmoil Amid Zillow's Earnings Shock

Updated Category News Views 212

Rocket Companies Stock Falls After Market Reactions Rocket Companies Inc (NYSE: RKT) is experiencing a downward trend as investors reassess their positions in housing-related stocks. This comes in the wake of a notable sell-off linked to Zillow Group Inc's disappointing earnings report, alongside growing trepidation surrounding artificial intelligence's impact on the real...

Continue Reading
Understanding Dimensional Fund Advisors Ltd.'s Recent Disclosure Actions

Updated Category News Views 139

Introduction to Dimensional Fund Advisors Ltd. Dimensional Fund Advisors Ltd. stands as a prominent investment management firm that focuses on providing high-quality investment solutions. Known for its innovative strategies, the firm has made significant strides in the financial sector. Public Opening Position Disclosure The recent public opening position disclosure by...

Continue Reading
Challenges Ahead for Dunxin Financial Following Delisting

Updated Category News Views 154

Understanding Dunxin Financial's Delisting Process NEW YORK - NYSE American LLC has initiated delisting proceedings for Dunxin Financial Holdings Limited, identified by the ticker symbol DXF for its American depositary shares (ADSs). This move by NYSE Regulation follows a determination that Dunxin Financial's shares do not meet the necessary listing standards, mainly due...

Continue Reading
Pro Music Rights Gains Official Approval as PRO in US Market

Updated Category News Views 198

Pro Music Rights Officially Recognized as a Performing Rights Organization Music Licensing, Inc. (OTC: SONG) has recently celebrated a significant milestone with the official recognition of its wholly-owned subsidiary, Pro Music Rights (PMR), as a Performing Rights Organization (PRO). This acknowledgment, appearing in the Federal Register, elevates PMR’s status in the...

Continue Reading
Dentsply Sirona Welcomes Aldo M. Denti as CCO to Innovate Sales

Updated Category News Views 206

Dentsply Sirona Appoints New Chief Commercial Officer Dentsply Sirona Inc. (NASDAQ: XRAY) has made a significant move to strengthen its commercial strategies by appointing Aldo M. Denti as its new Executive Vice President and Chief Commercial Officer. This change signals a commitment to enhancing customer experience and streamlining operations within the company....

Continue Reading